Progression of atrial fibrillation (AF) is caused by abnormalities in electrical conduction (‘electropathology’) which can be uncovered by applying a dedicated electrical stimulation technique. The severity of electropathology is indicated by the level of electrical biomarkers which can be used to individualize diagnosis and therapy of AF.
Findings of this project enable, for the first time, selection of the most appropriate treatment modality in the individual AF patient guided by electrical biomarkers. Individualized AF diagnosis and therapy will be more effective and most likely result in prevention of AF progression and related complications. In addition, new insights into AF-related electropathology make development of novel treatment strategies targeting areas of electrophatology possible.